-
公开(公告)号：US20120244112A1
公开(公告)日：2012-09-27
申请号：US13367843
申请日：2012-02-07
申请人： Oliver Ast , Peter Bruenker , Anne Freimoser-Grundschober , Sylvia Herter , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valeria G. Nicolini , Pablo Umana
发明人： Oliver Ast , Peter Bruenker , Anne Freimoser-Grundschober , Sylvia Herter , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valeria G. Nicolini , Pablo Umana
CPC分类号： C07K16/40 , A61K38/2013 , A61K47/6813 , A61K47/6849 , A61K47/6871 , A61K47/6891 , A61K2039/505 , C07K14/55 , C07K16/30 , C07K2319/00
摘要： The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
摘要翻译： 本发明一般涉及对IL-2受体的α亚基表现出降低的亲和力的突变白细胞介素-2多肽，用作免疫治疗剂。 此外，本发明涉及包含所述突变型IL-2多肽，编码突变型IL-2多肽或免疫缀合物的多核苷酸分子以及包含该多核苷酸分子的载体和宿主细胞的免疫缀合物。 本发明还涉及用于产生突变型IL-2多肽或免疫缀合物的方法，包含其的药物组合物及其用途。
-
公开(公告)号：US09266938B2
公开(公告)日：2016-02-23
申请号：US13367843
申请日：2012-02-07
申请人： Oliver Ast , Peter Bruenker , Anne Freimoser-Grundschober , Sylvia Herter , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valerla G. Nicolini , Pablo Umana
发明人： Oliver Ast , Peter Bruenker , Anne Freimoser-Grundschober , Sylvia Herter , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valerla G. Nicolini , Pablo Umana
CPC分类号： C07K16/40 , A61K38/2013 , A61K47/6813 , A61K47/6849 , A61K47/6871 , A61K47/6891 , A61K2039/505 , C07K14/55 , C07K16/30 , C07K2319/00
摘要： The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
摘要翻译： 本发明一般涉及对IL-2受体的α亚基表现出降低的亲和力的突变白细胞介素-2多肽，用作免疫治疗剂。 此外，本发明涉及包含所述突变型IL-2多肽，编码突变型IL-2多肽或免疫缀合物的多核苷酸分子以及包含该多核苷酸分子的载体和宿主细胞的免疫缀合物。 本发明还涉及用于产生突变型IL-2多肽或免疫缀合物的方法，包含其的药物组合物及其用途。
-
公开(公告)号：US09447159B2
公开(公告)日：2016-09-20
申请号：US13457039
申请日：2012-04-26
申请人： Oliver Ast , Peter Bruenker , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Pablo Umana
发明人： Oliver Ast , Peter Bruenker , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Pablo Umana
IPC分类号： C07K16/46 , C07K14/54 , C07K14/55 , A61K47/48 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/40 , A61K39/44 , C12N15/13 , C12N15/63 , C12N5/10 , C12P21/00
CPC分类号： C07K16/40 , A61K38/2013 , A61K39/395 , A61K47/6813 , A61K47/6843 , A61K47/6849 , A61K47/6851 , A61K47/6853 , A61K2039/505 , C07K14/52 , C07K14/5434 , C07K14/55 , C07K16/18 , C07K16/283 , C07K16/2866 , C07K16/30 , C07K16/3007 , C07K16/46 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/55 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/92 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/74
摘要： The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
摘要翻译： 本发明一般涉及用于选择性递送影响细胞活性的效应部分的抗原特异性免疫偶联物。 更具体地，本发明提供了包含第一抗原结合部分，Fc结构域和单个效应子部分的新型免疫偶联物。 此外，本发明涉及编码这种免疫缀合物的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。 本发明还涉及本发明的免疫缀合物的制备方法，以及使用这些免疫缀合物治疗疾病的方法。
-
公开(公告)号：US20120276125A1
公开(公告)日：2012-11-01
申请号：US13457039
申请日：2012-04-26
申请人： Oliver Ast , Peter Bruenker , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Pablo Umana
发明人： Oliver Ast , Peter Bruenker , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Pablo Umana
IPC分类号： C07K16/46 , C12N15/13 , A61P37/04 , C12N5/10 , C12P21/00 , A61K39/44 , C07K14/55 , C12N15/63
CPC分类号： C07K16/40 , A61K38/2013 , A61K39/395 , A61K47/6813 , A61K47/6843 , A61K47/6849 , A61K47/6851 , A61K47/6853 , A61K2039/505 , C07K14/52 , C07K14/5434 , C07K14/55 , C07K16/18 , C07K16/283 , C07K16/2866 , C07K16/30 , C07K16/3007 , C07K16/46 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/55 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/92 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/74
摘要： The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
摘要翻译： 本发明一般涉及用于选择性递送影响细胞活性的效应部分的抗原特异性免疫偶联物。 更具体地，本发明提供了包含第一抗原结合部分，Fc结构域和单个效应子部分的新型免疫偶联物。 此外，本发明涉及编码这种免疫缀合物的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。 本发明还涉及本发明的免疫缀合物的制备方法，以及使用这些免疫缀合物治疗疾病的方法。
-
公开(公告)号：US20120251529A1
公开(公告)日：2012-10-04
申请号：US13408171
申请日：2012-02-29
申请人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
发明人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
CPC分类号： C07K16/42 , A61K39/39566 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K16/3007 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
摘要翻译： 本发明提供了结合膜结合CEA的抗原结合分子（ABM），其包括具有改善的治疗性质的ABM及其使用方法。
-
公开(公告)号：US08642742B2
公开(公告)日：2014-02-04
申请号：US13408171
申请日：2012-02-29
申请人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
发明人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
IPC分类号： C07K16/30 , A61K39/395
CPC分类号： C07K16/42 , A61K39/39566 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K16/3007 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
摘要翻译： 本发明提供了结合膜结合CEA的抗原结合分子（ABM），其包括具有改善的治疗性质的ABM及其使用方法。
-
7.发明授权Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof 有权癌胚抗原（CEA）抗体，其制备方法及其应用公开(公告)号：US09068008B2
公开(公告)日：2015-06-30
申请号：US12872908
申请日：2010-08-31
CPC分类号： C07K16/3007 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/92
摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
摘要翻译： 本发明涉及抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体，包括特异于细胞表面或膜结合人CEA的嵌合，灵长类或人源化抗体或其变体。 此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.038 秒)